Amundi 13F: Adds $73M to Boston Scientific (BSX) Stake

Amundi Expands Holdings in Boston Scientific Corporation

Institutional investor Amundi grew its position in Boston Scientific Corporation NYSE BSX by 13.8%, purchasing an additional 1,707,754 shares during the period. According to a Form 13F filing with the Securities and Exchange Commission, the firm's total holding reached 14,122,913 shares. The reported value of this expanded stake stood at approximately $601.7 million. Because 13F filings are backward-looking documents, this update reflects positions held at the close of the reporting period and may not represent the investor's current allocation.

Position Details and Portfolio Context

The 13.8% increase follows prior adjustments by the firm in other equities earlier in the year. Amundi held 12,415,159 shares of the medical device maker prior to this latest addition. The estimated cost basis listed for the holding sits at $63.31 per share. Large asset managers routinely rebalance large portfolios across market sectors to manage risk and capture sector trends, though quarterly filings only reveal historical snapshots rather than day-to-day trading activity.

Stock Performance and Valuation Metrics

Shares of Boston Scientific traded around $42.60 on Friday. The company carries a market capitalization of roughly $64.0 billion. Looking at valuation, the stock posts a price-to-earnings ratio of 17.9 alongside a forward P/E ratio of 13.1. The medical device manufacturer has navigated a wide trading range, reaching a 52-week low of $41.39 and a 52-week high of $105.65. Its 50-day moving average rests at $46.18, while the 200-day moving average is tracked at $59.36.

Earnings and Financial Health

The Marlborough, Massachusetts-based company reported strong fundamental metrics in its financial updates. Annual revenue reached $21.0 billion, underpinned by a 7.5% revenue growth rate. Profitability measures include a net margin of 17.5% and a return on equity of 15.3%. Earnings per share stand at $2.47. Shareholders can look forward to the company's next scheduled earnings report on October 28, 2026.

Analysts Set New Price Targets

Wall Street firms have continued to update their outlooks on the healthcare sector. On October 14, 2026, Truist Securities maintained its buy rating on the stock while adjusting its price target to $51.00. Earlier in October, Barclays initiated coverage with an equal-weight rating and a $48.00 target, while Citigroup maintained a neutral rating with a $48.00 target. Oppenheimer holds an outperform rating with a $65.00 target. Across the broader analyst community, the stock holds a consensus buy recommendation with a mean price target of $59.24 derived from 29 analyst opinions.

Medical Device Innovation and Operations

Boston Scientific Corporation develops and markets medical devices used in interventional medical specialties worldwide through its MedSurg and Cardiovascular segments. The firm provides products for gastroenterology, urology, and neuromodulation, alongside cardiac rhythm management and structural heart devices like the WATCHMAN FLX. Founded in 1979, the company employs approximately 59,000 people globally.

What to Watch at Boston Scientific Corporation

Investors tracking institutional interest in Boston Scientific will look to subsequent SEC disclosures to see if Amundi and other major asset managers continue expanding their positions. The upcoming earnings release on October 28, 2026, will provide fresh financial data on revenue growth and profit margins.